CUSIP No. 705324 10 1 Page 1 of 6 Pages
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
(Rule 13d-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
RULE 13d-2(a)
(Amendment No. 2)1
Pediatrix Medical Group, Inc.
-------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $.01 par value
-------------------------------------------------------------------------------
(Title of Class of Securities)
705324 10 1
-------------------------------------------------------------------------------
(CUSIP Number)
Welsh, Carson, Anderson Othon A. Prounis, Esq.
& Stowe Reboul, MacMurray, Hewitt,
320 Park Avenue, Suite 2500 Maynard & Kristol
New York, New York 10022 45 Rockefeller Plaza
Attention: Jonathan Rather New York, New York 10111
Tel. (212) 893-9500 Tel. (212) 841-5700
-------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
August 20, 2001
-------------------------------------------------------------------------------
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the
following box [ ].
--------
1 The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter disclosures provided in a prior cover page. The information required on
the remainder of this cover page shall not be deemed to be "filed" for the
purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise
subject to the liabilities of that section of the Act but shall be subject to
all other provisions of the Act.
CUSIP No. 705324 10 1 Page 2 of 6 Pages
1) Name of Reporting Person Welsh, Carson, Ander-
and I.R.S. Identification son & Stowe VII, L.P.
No. of Above Person, if
an Entity (Voluntary)
-------------------------------------------------------------------------------
2) Check the Appropriate Box (a) [X]
if a Member of a Group (b) [ ]
-------------------------------------------------------------------------------
3) SEC Use Only
-------------------------------------------------------------------------------
4) Source of Funds Not Applicable
-------------------------------------------------------------------------------
5) Check if Disclosure of
Legal Proceedings Is Not Applicable
Required Pursuant to
Items 2(d) or 2(e)
-------------------------------------------------------------------------------
6) Citizenship or Place
of Organization Delaware
-------------------------------------------------------------------------------
Number of 7) Sole Voting 2,757,877 shares of
Shares Beneficially Power Common Stock
Owned by Each
Reporting Person
-------------------------------------------------
8) Shared Voting
Power -0-
-------------------------------------------------
9) Sole Disposi- 2,757,877 shares of
tive Power Common Stock
-------------------------------------------------
10) Shared Dis-
positive Power -0-
-------------------------------------------------
11) Aggregate Amount Beneficially 2,757,877 shares of
Owned by Each Reporting Person Common Stock
-------------------------------------------------------------------------------
12) Check if the Aggregate
Amount in Row (11)
Excludes Certain Shares
-------------------------------------------------------------------------------
13) Percent of Class
Represented by 11.7%
Amount in Row (11)
-------------------------------------------------------------------------------
14) Type of Reporting
Person PN
CUSIP No. 705324 10 1 Page 3 of 6 Pages
1) Name of Reporting Person WCAS Healthcare
and I.R.S. Identification Partners, L.P.
No. of Above Person, if
an Entity (Voluntary)
-------------------------------------------------------------------------------
2) Check the Appropriate Box (a) [X]
if a Member of a Group (b) [ ]
-------------------------------------------------------------------------------
3) SEC Use Only
-------------------------------------------------------------------------------
4) Source of Funds Not Applicable
-------------------------------------------------------------------------------
5) Check if Disclosure of
Legal Proceedings Is Not Applicable
Required Pursuant to
Items 2(d) or 2(e)
-------------------------------------------------------------------------------
6) Citizenship or Place
of Organization Delaware
-------------------------------------------------------------------------------
Number of 7) Sole Voting 57,673 shares of
Shares Beneficially Power Common Stock
Owned by Each
Reporting Person
-------------------------------------------------
8) Shared Voting
Power -0-
-------------------------------------------------
9) Sole Disposi- 57,673 shares of
tive Power Common Stock
-------------------------------------------------
10) Shared Dis-
positive Power -0-
-------------------------------------------------
11) Aggregate Amount Beneficially 57,673 shares of
Owned by Each Reporting Person Common Stock
-------------------------------------------------------------------------------
12) Check if the Aggregate
Amount in Row (11)
Excludes Certain Shares
-------------------------------------------------------------------------------
13) Percent of Class
Represented by 0.2%
Amount in Row (11)
-------------------------------------------------------------------------------
14) Type of Reporting
Person PN
CUSIP No. 705324 10 1 Page 4 of 6 Pages
Amendment No. 2 to Schedule 13D
-------------------------------
Reference is hereby made to the statement on Schedule 13D filed with
the Commission on May 22, 2001, as amended by Amendment No. 1 thereto filed on
May 29, 2001 (as so amended, the "Schedule 13D"). Terms defined in the Schedule
13D are used herein as so defined.
Item 5 is hereby amended and restated to read in its entirety as
follows:
Item 5. Interest in Securities of the Issuer.
-------------------------------------
The following information is based on a total of 23,640,542 shares
of Common Stock outstanding as of August 7, 2001, as reported in the Issuer's
Report on Form 10-Q for the period ended June 30, 2001 filed with the Commission
on August 14, 2001:
(a)
WCAS VII and VII Partners
-------------------------
WCAS VII owns 2,757,877 shares of Common Stock, or approximately
11.7% of the Common Stock outstanding. VII Partners, as the general partner of
WCAS VII, may be deemed to beneficially own the securities owned by WCAS VII.
WCAS HP and HP Partners
-----------------------
WCAS HP owns 57,673 shares of Common Stock, or approximately 0.2% of
the Common Stock outstanding. HP Partners, as the general partner of WCAS HP,
may be deemed to beneficially own the securities owned by WCAS HP.
General Partners of VII Partners and HP Partners
-------------------------------------------------
(i) Patrick J. Welsh owns 23,892 shares of Common Stock, or
approximately 0.1% of the Common Stock outstanding.
(ii)Russell L. Carson owns 23,892 shares of Common Stock, or
approximately 0.1% of the Common Stock outstanding.
(iii) Bruce K. Anderson owns 23,892 shares of Common Stock, or
approximately 0.1% of the Common Stock outstanding.
(iv) Thomas E. McInerney owns 18,949 shares of Common Stock, or less
than 0.1% of the Common Stock outstanding.
(v) Robert A. Minicucci owns 8,238 shares of Common Stock, or less
than 0.1% of the Common Stock outstanding.
(vi) Anthony J. deNicola owns 2,471 shares of Common Stock, or less
than 0.1% of the Common Stock outstanding.
CUSIP No. 705324 10 1 Page 5 of 6 Pages
(vii) Paul B. Queally owns 4,943 shares of Common Stock, or less
than 0.1% of the Common Stock outstanding.
(viii) Lawrence B. Sorrel owns no shares of Common Stock.
(ix) Jonathan M. Rather owns no shares of Common Stock.
(b) The general partners of VII Partners and HP Partners may be
deemed to share the power to vote or direct the voting of and to dispose or
direct the disposition of the Common Stock owned by WCAS VII and WCAS HP,
respectively. Each of the general partners of VII Partners and HP Partners
disclaims beneficial ownership of shares of Common Stock other than those he
owns directly or by virtue of his or her indirect pro rata interest, as a
general partner of VII Partners and/or HP Partners, as the case may be, in the
securities owned by WCAS VII and/or WCAS HP.
(c) On dates between August 14, 2001 and August 22, 2001, WCAS VII
sold an aggregate 314,061 shares of Common Stock in open market transactions, at
a weighted average sale price of $36.23 per share.
(d) Except as described in this statement, no person has the power
to direct the receipt of dividends on or the proceeds of sales of the shares of
Common Stock owned by WCAS VII or WCAS HP.
(e) Not Applicable.
CUSIP No. 705324 10 1 Page 6 of 6 Pages
Signature
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
WELSH, CARSON, ANDERSON & STOWE VII, L.P.
By: WCAS VII Partners, L.P.,
General Partner
By: /s/ Jonathan Rather
-------------------------
General Partner
WCAS HEALTHCARE PARTNERS, L.P.
By: WCAS HP Partners, General Partner
By: /s/ Jonathan Rather
-------------------------
Attorney-in-Fact
Dated: August 28, 2001